Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study Strong financial position with $182.5 million in cash, cash equivalents and marketable securities expected to support operations into the ...